TGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical Data

• Earlier this month, TG Therapeutics reported positive early results for a new under-the-skin version of BRIUMVI in patients with myasthenia gravis.
• Prior to that, the company also released encouraging early data showing that the under-the-skin shot is well absorbed by the body and works similarly to the IV version.
• Briumvi is TG Therapeutics’ only commercial product, after being approved for Multiple Sclerosis in late 2022.

Shares of TG Therapeutics Inc (TGTX) jumped as much as 5% on Wednesday before paring gains as investor optimism remains buoyed by recent subcutaneous BRIUMVI clinical data, which sparked excitement on the long-term growth potential of the drug.

The stock closed up 2%, marking its eighth consecutive day of closing in the green.

June Announcements Drive Optimism For Subcutaneous Briumvi

Earlier this month, TG Therapeutics reported positive early results for a new under-the-skin version of BRIUMVI in patients with myasthenia gravis, a disease that causes muscle weakness. In a small early study involving 11 patients, most saw clear improvements in their daily symptoms after six months, the company said.

The treatment was generally safe and well-tolerated, with a profile similar to the current IV version already used for multiple sclerosis. The company has now started a new mid-stage trial to test combining BRIUMVI with another drug for faster initial relief followed by longer-term control.

Prior to that, the company also released encouraging early data showing that the under-the-skin shot is well absorbed by the body and works similarly to the IV version. The results supported dosing every two or three months instead of more frequent clinic visits and raised the possibility of convenient at-home self-injections in the future.

BRIUMVI Sales Strength

BRIUMVI is TG Therapeutics’ only commercial product, after being approved for Multiple Sclerosis in late 2022.

In the first quarter of 2026, the company reported about $205 million in global revenue and raised its full-year sales forecast to roughly $925 million. Of the overall revenue, $194.8 million came from U.S. BRIUMVI net product sales and another $6.5 million from BRIUMVI sales to their ex-U.S. partner.

How Did TGTX Retail Traders React?

On Stocktwits, retail sentiment around TGTX fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume dipped from ‘extremely high’ to ‘high’ levels.

A Stocktwits user said that the stock is “still way undervalued” and voiced hopes for the next catalyst driving up share prices.

Another user applauded the stock breaching the $50 mark.

According to data from Koyfin, seven of the nine analysts covering TGTX rate it ‘Buy’ or higher, while one rates it ‘Hold’ and one ‘Strong Sell.’ The 12-month average price target on the stock is $48, representing a potential downside of 7% from Wednesday’s closing price

TGTX stock has gained 76% this year. 

Read More: EOSE Stock Climbs On Dual Catalysts: Europe Deal And U.S. Factory Ramp

For updates and corrections, email newsroom[at]stocktwits[dot]com.